Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as STAT3 Inhibitor WP1066
WP1066 · 1 trial · 2 indications
For PFS analysis, disease progression is defined as progressive disease (PD) per Response Assessment in Neuro-Oncology (RANO) criteria Will be summarized using the Kaplan-Meier method.
| Arm | Type | Description |
|---|---|---|
| Cohort I (WP1066, radiation) | EXPERIMENTAL | Patients whose tumor was completely removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy, and then for twelve 28-day cycles on study. Patients also undergo MRI and collection of blood samples throughout the trial. |
| Cohort II (WP1066, radiation, surgery) | EXPERIMENTAL | Patients whose tumor was not fully removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy on study. Patients may then undergo possible surgery or open biopsy if eligible, followed by twelve 28-day cycles of WP1066 PO on study. Patients also undergo MRI and collection of blood samples throughout the trial. |
| Name | Type | Description |
|---|---|---|
| Biospecimen Collection | PROCEDURE | Undergo collection of blood |
| Magnetic Resonance Imaging | PROCEDURE | Undergo MRI |
| Radiation Therapy | RADIATION | Undergo routine radiation therapy |
| STAT3 Inhibitor WP1066 | DRUG | Given PO |
| Surgical Procedure | PROCEDURE | Undergo removal or biopsy of tumor |
Inclusion Criteria: * Newly diagnosed, histologically confirmed World Health Organization (WHO) glioblastoma multiforme (GBM), IDH wild-type * External pathology reports are permitted for confirmation of histological diagnosis * Documentation of isocitrate dehydrogenase (IDH) wild-type status ...